WeVote
Log In

Bill

Bill

S 9279

Relates to the operation of gene synthesis providers and manufacturers of gene synthesis equipment

2025 Regular Session Introduced by Mike Gianaris

New York will regulate gene synthesis providers and equipment makers, with the Department of Health creating rules based on industry standards to improve biosafety and biosecurity.

2ND REPORT CAL.
0
WeVote Research Nonpartisan
Bill Summary · S 9279

Overview

  • Bill: S 9279
  • Session: 2025-2026
  • Jurisdiction: New York
  • Title: Relates to the operation of gene synthesis providers and manufacturers of gene synthesis equipment
  • Purpose: Establish a regulatory framework to govern gene synthesis providers and manufacturers of gene synthesis equipment (bioterrorism prevention)

Main purpose and intent

  • Create standards and regulations for entities that synthesize and/or distribute synthetic nucleic acids and the equipment used for gene synthesis.
  • Align with generally accepted industry standards and incorporate guidance from recognized international and national organizations (e.g., International Gene Synthesis Consortium) in the development of rules.
  • Position the state to mitigate risks associated with misuse of gene synthesis capabilities.

Key provisions and changes

  • New Article: Article 32-B added to the Public Health Law, titled “GENE SYNTHESIS LABS.”
  • Section 3230: Operation of gene synthesis providers and manufacturers of gene synthesis equipment
    • Any gene synthesis provider or manufacturer of lab equipment intended for use by a gene synthesis provider must operate in accordance with rules and regulations issued by the New York Department of Health (the department).
    • The department must draft these rules using generally accepted industry standards and consider recommendations and protocols from:
    • The International Gene Synthesis Consortium (IGSC)
    • Other nationally or internationally recognized, relevant organizations
    • Definitions:
    • “Gene synthesis provider” means any entity that synthesizes and distributes synthetic nucleic acids to a customer or to a distributor.
  • Effective date: The act takes effect immediately upon enactment.

Who/what is affected

  • Gene synthesis providers (companies that synthesize and distribute synthetic nucleic acids).
  • Manufacturers of gene synthesis equipment used by gene synthesis providers.
  • The Department of Health (state regulatory authority) responsible for issuing implementing rules and regulations.
  • Potentially customers of gene synthesis providers and manufacturers, as regulated entities may need to comply with new rules.

Procedural and timeline aspects

  • Introduction and legislative path:
    • Introduced February 24, 2026.
    • Referred to the Senate Committee on Health.
    • Subsequent actions include amendments and recommitments within 2026 legislative steps.
  • Effective date:
    • Immediate effect upon enactment (no delayed effective date stated).

Practical impact and considerations

  • Compliance requirements:
    • Affected entities must align operations with department-issued rules.
    • Rules will be informed by established industry standards and IGSC guidance, potentially including screening, screening protocols for sequences, verification processes, and other biosafety/biosecurity practices (specific rules to be issued by the department).
  • Oversight and enforcement:
    • The Department of Health would regulate and enforce compliance with the new article.
  • Clarity and scope:
    • The bill relies on future rulemaking to specify concrete standards and procedures; the exact requirements will depend on the department’s regulations and the referenced international/national guidance.

Summary

S 9279 creates a new regulatory framework within New York’s public health law to govern gene synthesis providers and gene synthesis equipment manufacturers. It directs the Department of Health to adopt rules based on generally accepted industry standards and guidance from recognized bodies, with the aim of enhancing biosafety and biosecurity in the gene synthesis sector. The act takes effect immediately upon enactment.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.